LEXINGTON, Mass. — Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that they will be attending the AACC Annual Meeting and Clinical Lab Expo on July 28 – August 1, 2013 in Houston, Texas. Quanterix will be presenting research based on its Single Molecule Array technology called Simoa, which is capable of measuring individual proteins at concentrations 1,000 times lower than the best immunoassays and is now commercially available for biomedical research. Dr. David Wilson, Vice President of Product Development, will be speaking on the application of Simoa to HIV screening, where the technology allows far earlier and more sensitive detection than any existing immunoassay. Additionally, Dr. David Duffy, Vice President, Research and Chief Technology Officer of Quanterix will present an industry workshop focused on educating attendees about the scientific principles of Simoa and clinical studies demonstrating its utility in oncology, cardiology, neurology, inflammation, and other therapeutic areas.

Session Details:

Lunch & Learn— Clinical Utility of Ultra-Sensitive HIV Assay

Monday, July 29, 2013 at 12:00 – 2:30 p.m.

Hilton Americas Houston, Meeting Room 335A

Dr. David Wilson will participate in AACC’s Clinical Translational Science Division Annual Meeting – Lunch and Learn, the theme of which is “Next Generation Tools for High to Ultra-Sensitive Measurements” and deliver a presentation on the clinical utility of ultra-sensitive HIV assays. During this presentation, attendees will learn about the 3000x improvement in sensitivity Simoa offers for measuring the p24 protein commonly used in HIV screening and its implications for blood screening.

Industry Workshop— A Digital Immunoassay Revolution: Counting Single Molecules with an Ultrasensitive ELISA Platform

Wednesday, July 31, 2013 at 7:00 – 8:30 a.m.

Hyatt Regency Houston, Window Box

Dr. David Duffy will lead a session on digital immunoassays and ultrasensitive, single molecule measurement. During this presentation, attendees will learn about the fundamental scientific principles that make it possible to count individual biomarker molecules using the Simoa technology. Dr. Duffy will also describe a number of studies across a broad range of therapeutic areas that show the possible clinical relevance of such ultrasensitive measurements.

Poster Session— Determination of Cardiac Troponin with a Single-Molecule High-Sensitivity Assay and Outcomes in Patients with Stable Coronary Artery Disease: Analysis from PROVE IT-TIMI 22

Wednesday, July 31, 2013 at 9:30 a.m. – 5:00 p.m.

Presented by Dr. Lei Chang, Principal Scientist, Quanterix in Section B219 in Cardiac Markers

Connect with Quanterix at the AACC Annual Meeting and Clinical Lab Expo:

For more information on Quanterix and Simoa technology, please visit them at booth #1504 and to learn more about the event, please visit: https://www.aacc.org/events/annual_meeting/pages/default.aspx.

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com/simoa-is-here.